930781-28-5

Upstream product

• 80058-84-0 4-bromo-2,6-diisopropylaniline 
• 74-88-4 methyl iodide 
• 50-00-0 formaldehyd 
• 64-18-6 formic acid 

Downstream Products

• 930781-29-6 bis(4-dimethylamino-3,5-diisopropylphenyl)phosphine oxide 
• 1616979-90-8 4,4'-(tert-butylphosphinediyl)bis(2,6-diisopropyl-N,Ndimethylaniline) 
• 1616980-19-8 C₃₂H₅₃N₂PSe 

Relevant academic research and scientific papers

Aryl-Diadamantyl Phosphine Ligands in Palladium-Catalyzed Cross-Coupling Reactions: Synthesis, Structural Analysis, and Application

Synthesis, temperature-dependent NMR structure investigation and utilization of a new, stable and easily accessible aryl-diadamantylphosphine ligand family is reported. The bulky and electron-rich phosphorus center of the ligand enhances the catalytic activity of palladium in cross-coupling reactions of sterically demanding ortho-substituted aryl halides. In our study, we demonstrated the synthetic applicability of the new phosphine ligands in Buchwald-Hartwig and tosyl hydrazone coupling reactions.

Synthesis and photoinitiating properties of N-substituted 2,6-diisopropylanilines

Reactions of 2,6-diisopropylaniline and its 4-bromo and 4-thiocyanato derivatives with methyl iodide in dimethylformamide in the presence of potassium carbonate gave exclusively the corresponding N,N-dimethyl-substituted products. Heating of 2,6-diisopropylaniline and 2,6-diisopropyl-4-thiocyanatoaniline with methyl iodide without a solvent afforded only N-methyl derivatives. Pleiades Publishing, Ltd., 2011.

NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS

The invention relates to compounds corresponding to general formula (I) below: to the compositions containing same, to methods for the preparation thereof and to the use thereof in pharmaceutical compositions for use in human or veterinary medicine, or else in cosmetic compositions.

DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME

The present invention provides a novel ligand represented by the following formula and a novel transition metal complex having the ligand, which shows superior enantioselectivity and catalytic efficiency, particularly high catalyst activity, in various asymmetric synthesis reactions. A transition metal complex having, as a ligand, a compound represented by the formula wherein R4 is a hydrogen atom or a C1-6 alkyl group optionally having substituent(s), and R5 and R6 are each a C1-6 alkyl group optionally having substituent(s), or the formula is a group represented by the formula wherein ring B is a 3- to 8-membered ring optionally having substituent (s).